INHIBITOR OF ATR

The CNIO has developed inhibitors of ataxia telangiectasia mutated and Rad3-related kinase (ATR).

Industrial partners are being sougth to collaborate through a patent license agreement for the development and exploitation of the technology.

Description

The inventors have found novel chemical entities with anti-cancer activity, and more specifically to chemical entities that inhibit ATR (Ataxia telangiectasia mutated and Rad3-related kinase). This invention also relates to pharmaceutical compositions containing, and the uses of, such chemical entities.

Main innovations and advantages

The present invention relates to a series of tricyclic chemical entities that are inhibitors of ATR. These chemical entities demonstrate good selectivity for ATR and are potentially useful in the treatment of cancer. The invention further relates to pharmaceutical compositions of the chemical entities, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions. In an aspect, the present invention provides chemical entities selected from compounds of formula (I).



(I)

Intellectual property

Patent title :

"CHEMICAL ENTITIES"

Applicant: Spanish National Cancer Research Center (CNIO)

International patent application:

WO2014140644

Patent extended/granted in: Australia, Brasil, Canada, Chile, China, Colombia, Ecuador, Europe, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Peru, Philippines, Russia, Singapore, South Africa Thailand,Taiwan, Ukraine and USA.

For more information, please contact:

Technology Transfer and Valorization Office
Centro Nacional de Investigaciones Oncológicas
C/ Melchor Fernández Almagro, 3
28029 Madrid Spain
technologytransfer@cnio.es
www.cnio.es
@CNIO_Cancer